Innovation and development of generic pharmaceuticals
pharmaphorum
MAY 18, 2023
Innovation and development of generic pharmaceuticals Mike.Hammerton Thu, 05/18/2023 - 10:17 Bookmark this
pharmaphorum
MAY 18, 2023
Innovation and development of generic pharmaceuticals Mike.Hammerton Thu, 05/18/2023 - 10:17 Bookmark this
Pharmaceutical Technology
FEBRUARY 28, 2023
KFA-115 is under clinical development by Novartis and currently in Phase I for Melanoma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
BioTech 365
MARCH 12, 2021
Amring Pharmaceuticals Inc. Enters into License and Development Agreement with Amzell B.V. Amring Pharmaceuticals Inc. Enters into License and Development Agreement with Amzell B.V. –(BUSINESS WIRE)–Amring Pharmaceuticals Inc. BERWYN, Pa.–(BUSINESS
Pharmaceutical Technology
JUNE 1, 2023
Dipharma is a pioneer in developing improved generic pharmaceutical products for rare diseases: our desire to innovate and our engagement do not stop, but every day we continue to seek new and better solutions for patients around the world.”
BioTech 365
AUGUST 4, 2021
the “Company”) (OTC PINK:SHMN), a generic Pharmaceutical, Nutraceutical, and Cosmeceutical company that manufactures and markets generic … Continue reading → Chino Hills, 08/04/2021 / 15:52, CET/CEST – EQS Newswire – Sohm, Inc. CHINO HILLS, CA / ACCESSWIRE / August 4, 2021 / SOHM, Inc.
Pharmaceutical Technology
FEBRUARY 28, 2023
KFA-115 is under clinical development by Novartis and currently in Phase I for Malignant Mesothelioma. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
Pharmaceutical Technology
FEBRUARY 28, 2023
Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Paroxysmal Nocturnal Hemoglobinuria. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.
Let's personalize your content